REG - Eco Animal Health Gp - Exercise of Share Options by Director

ECO Animal HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0209Ma&default-theme=true

RNS Number : 0209M  Eco Animal Health Group PLC  18 December 2025

18 December 2025

 

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Exercise of Share Options and Director/PDMR Shareholdings

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal
health company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that Christopher Wilks, Chief
Financial Officer, has exercised 4,309 nominal cost share options granted
under the Company's Deferred Bonus Share Options scheme (the "Scheme"). These
share options were granted on 12 December 2022 as a deferral of one-third of
Mr Wilks' bonus relating to the year ended 31 March 2022.

The exercise has been fully satisfied through the transfer of existing
ordinary shares held by the ECO Animal Health Group Employee Benefit Trust
("EBT"). No new ordinary shares have been issued in connection with this
transaction.

As a result of this transaction, Mr. Wilks' total beneficial shareholding in
the Company is now 178,186 ordinary shares, representing approximately 0.26%
of the Company's issued share capital ("ISC").

Therefore, the total number of ordinary shares with voting rights in the
Company remains at 67,759,671. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in the
Group under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

The notifications below, provided in accordance with the requirements of the
UK Market Abuse Regulation, provide further details

-Ends-

For further information please contact:

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Samed Ethemi

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

 1.                          Details of the person discharging managerial responsibilities / person closely
                             associated
 a.                          Name                                       Christopher Wilks
 2.                          Reason for the notification
 a.                          Position/status                            Chief Financial Officer

 b.                          Initial notification                       Initial notification

                             /Amendment

 3.                          Details of the issuer, emission allowance market participant, auction
                             platform, auctioneer or auction monitor
 a.                          Name                                       Eco Animal Health Group Plc
 b.                          LEI                                        2138009XN9DJ3YP7OB55
 4.                          Details of the transaction(s): section to be repeated for (i) each type of
                             instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                             place where transactions have been conducted
 a.                          Description of the                         Options over ordinary shares of 5p each.

                             Financial instrument, type of instrument

                             Identification code                        GB0032036807

 b.                          Nature of the transaction                  1.    Nominal cost share awards under the Company's Deferred Bonus Share
                                                                        Options ("DBS").
 c.                          Price(s) and volume(s)

     Price(s)  Volume(s)

                                                                        2.  DBS  5p        4,309

 
 d.                          Aggregated information

                             Aggregated volume

                             Price                                      n/a

 e.                          Date of the transaction                    17 December 2025
 f.                          Place of the transaction                   Off Market

 

d.

Aggregated information

Aggregated volume

Price

 

 

n/a

 

e.

Date of the transaction

17 December 2025

f.

Place of the transaction

Off Market

 

 

( )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZMMZLNKGKZM



            Copyright 2019 Regulatory News Service, all rights reserved